Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $6.34 Consensus Target Price from Brokerages

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has earned a consensus recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $6.34.

A number of research analysts recently weighed in on MRVI shares. Robert W. Baird cut shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $9.00 to $3.00 in a research note on Wednesday, February 26th. Baird R W lowered Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. UBS Group decreased their target price on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Morgan Stanley dropped their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 25th. Finally, Bank of America reduced their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd.

Maravai LifeSciences Price Performance

NASDAQ MRVI opened at $2.05 on Monday. The stock has a market cap of $521.39 million, a price-to-earnings ratio of -1.25 and a beta of 0.18. Maravai LifeSciences has a 12 month low of $1.67 and a 12 month high of $11.56. The company’s 50 day moving average is $2.45 and its two-hundred day moving average is $4.61. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Insider Buying and Selling

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the sale, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.63% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MRVI. SG Americas Securities LLC raised its position in Maravai LifeSciences by 2,005.9% during the first quarter. SG Americas Securities LLC now owns 695,907 shares of the company’s stock valued at $1,538,000 after purchasing an additional 662,861 shares during the period. Simplicity Wealth LLC bought a new position in shares of Maravai LifeSciences during the 1st quarter valued at approximately $67,000. Alpha Wealth Funds LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $386,000. Delta Investment Management LLC lifted its position in Maravai LifeSciences by 285.4% in the fourth quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock worth $1,815,000 after buying an additional 246,592 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Maravai LifeSciences by 22.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock worth $1,369,000 after buying an additional 45,454 shares during the period. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.